semaglutide chronic kidney disease

Ozempic receives FDA nod for treating chronic kidney disease

FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease,

Medscape · 1d

Ozempic Receives New Indications in Chronic Kidney Disease

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with chronic kidney disease.

The New York Times · 2d

F.D.A. Approves Ozempic to Treat Kidney Disease

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have both Type 2 diabetes and chronic kidney disease.

The American Journal of Managed Care1d

FDA Expands Semaglutide Use for CV, Kidney Risks in T2D, CKD

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

Rolling Out11d

How semaglutide is transforming kidney disease treatment

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential ...

Irish Examiner5h

Inquest finds Cork grandmother died of total organ failure three months after starting on Ozempic

Pathologist Dr Margot Bolster said Breeda O’Donoghue's death should be referred to the Health Products Regulatory Authority ...

Endocrinology Advisor1d

Real-World Effectiveness of GLP-1 RA vs DPP4i in Moderate to Severe CKD Explored

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Ozempic receives FDA nod for treating chronic kidney disease

Related topics